Today, there is no reliable way to determine which immunotherapy a cancer patient will respond to. Current “omics” solutions fall short for predicting response to immunotherapy. The biological complexity of a live sample is too intricate for traditional approaches to measure.
Because of this, only 1 in 5 patients respond to immunotherapy today
At ElephasTM Biosciences, we aim to close the gap in the ability to predict immunotherapy response with an innovative platform